Scientists from King's College London have successfully applied a new technology that disarms one of the most potent weapons ...

Merck (MRK) and Eisai (ESAIY) announced results from the Phase 3 LEAP-012 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima, the ...

After a progression-free survival win last year raised hopes for the combo's potential in hepatocellular carcinoma, an overall survival miss brings the study to a close.

For lenvatinib (Lenvima), which can cause hypertension, patients’ baseline blood pressure should be considered, and they should be monitored for the first 4 to 6 weeks. He recommends oncologists ...

Exelixis’ oral tyrosine kinase inhibitor (TKI) was tied to a 20% reduced risk of death from colorectal cancer, appearing to ...

From week 16, patients who were randomized to placebo were switched to deucravacitinib, while those who received deucravacitinib initially remained on treatment through week 52.

of patients treated with ensartinib reached 24-month disease-free survival, compared to 53.5% in the placebo control arm.

Sacituzumab tirumotecan significantly reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The ...

"Multiple sclerosis: three trials to watch" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.